Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New EU Filings

Executive Summary

Tabelecleucel, Atara Biotherapeutics’ advanced therapy for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease, is among the latest new medicines that have been submitted for review for potential pan-EU approval.

You may also be interested in...



Seventeen And Counting – Bumper Crop Of New EU Filings

Orphan drugs and COVID-19 products are among the latest filings under review by the European Medicines Agency for potential pan-EU approval.

First Academic Sponsor On EMA’s PRIME Pledges Cheaper CAR-Ts

An investigational CAR T-cell therapy that hospital researchers in Spain believe they could produce at a third of the price of commercially available CART19 products has been accepted onto the European Medicines Agency's priority medicines scheme.

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add one new product – Lumykras, Amgen’s treatment for advanced non-small cell lung cancer.

Topics

UsernamePublicRestriction

Register

PS145326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel